Bally’s Corporation (NYSE: BALY) eyes evoke plc (LSE: EVOK): why a William Hill deal would reshape UK gambling
Read More Pharma Industry News Neumora (NASDAQ: NMRA) to begin Phase 1 trial of oral NLRP3 obesity pill in early 2026: Can it rival GLP-1 pills? Find out how Neumora Therapeutics’ oral obesity candidate NMRA‑215 is advancing to human trials. Could it reshape the future of weight loss therapies? byPallavi MadhirajuOctober 28, 2025